• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Clout, Not Costs, Drives Higher Charges from Hospitals, Study Says

Article

Bargaining leverage, not the cost of providing complex care, is the main reason why some hospitals can demand prices twice as high as their competitors' and still get contracts to treat privately insured patients, according to a new study.

Bargaining leverage, not the cost of providing complex care, is the main reason why some hospitals can demand prices twice as high as their competitors' and still get contracts to treat privately insured patients, according to a new study.

The analysis by the Center for Studying Health System Change of actual payments to hospitals and physicians by private insurers in 13 U.S. cities found that the most expensive hospitals got rates as much as 60% more than the lowest-priced competitor for inpatient care, and prices that were double the competition for outpatient care.

The outpatient differences were particularly stark in three markets—Indianapolis, Kansas City, Mo., and Toledo, Ohio—where private insurers paid the most expensive hospitals more than four times what Medicare would have allowed for the same services.

Read the full story here: http://bit.ly/13j08x0

Source: Modern Healthcare

The study drew comparisons between private insurance payments to hospitals and primary-care physicians to make its point. While the most expensive hospitals charged prices far exceeding their lower-priced competitors, study authors found that primary-care doctors don't command the same mark-up power. Some family practice doctors actually received lower rates from private insurers than they did from the famously stingy Medicare program, the study found.

Related Videos
Screenshot of an interview with James Chambers, PhD
dr ian neeland
dr manisha jhamb
dr john m. o'brien
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
Ali Khawar
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.